Blogs | MedChemExpress

RLA-5331 is an Iron Activator Containing Anti-androgen

RLA-5331 is an iron activator containing anti-androgen. RLA-5331 is used for metastatic castrated tolerant prostate cancer (mCRPC) research.
Xentuzumab is a Monoclonal Antibody That Targets IGF Ligands IGF1 and IGF2

Xentuzumab is an anti-IGF-1/2 mAb, also targets to INSR-A. Xentuzumab inhibits tumor proliferation and induces apoptosis.
ARD-69 is a Potent PROTAC Androgen Receptor Degrader

ARD-69 is a potent PROTAC androgen receptor degrader and induces degradation of AR protein in AR-positive prostate cancer cell lines.
KGP94 is a Selective Inhibitor of Cathepsin L for Cancer Research

KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
Rucaparib (AG014699) is an Orally Active PARP-1/2/3 Inhibitor

Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with IC50s <5 nM , possessing anticancer activity.
Indoximod, An Immunometabolic Adjuvant, is an IDO Pathway Inhibitor

Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
Rucaparib is a PARP Inhibitor

Rucaparib is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3). Rucaparib has the potential for CRPC research.
XL092 is a Potent Axl, Mer and C-Met kinase Inhibitor

XL092 is a potent inhibitor of the activity of Axl, Mer and C-Met kinase with IC50s of <10 nM, respectively. Anti-tumor Activity.
Apitolisib is an Orally Active Class I PI3K and mTORC1/2 Inhibitor

Apitolisib is a potent Class I PI3 kinase and mTORC1/2 inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/β/δ/γ, respectively.
Anisomycin, a Protein Synthesis Inhibitor, also Interferes DNA Synthesis

Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis. Anisomycin is a JNK activator.

Name
Email *

	Sorry, but the email address you supplied was invalid.

Blogs (49)